Les réactions cutanées consécutives à l'induction anesthésique au mivacurium

Miloudi, Youssef; Harrar, N. El; Bensaid, A.; Hussein, Mohamed A.

doi:10.1016/j.annfar.2007.04.002

Cited by 1 publication

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated histamine levels were frequently observed when measured, sometimes in more than 50% of patients (70)(71)(72)(73). Flushing/erythema has been observed in from 6% to 73% of patients (70)(71)(72)(74)(75)(76)(77)(78)(79)(80)(81)(82). MAP changes also occur at a lesser frequency, from 0% to 50% (70,72,73,77,(80)(81)(82)(83).…”

Section: Allergic-type Event Frequency and Mast Cell Dependencementioning

confidence: 98%

“…Flushing/erythema has been observed in from 6% to 73% of patients (70)(71)(72)(74)(75)(76)(77)(78)(79)(80)(81)(82). MAP changes also occur at a lesser frequency, from 0% to 50% (70,72,73,77,(80)(81)(82)(83). Studies that examined all at once found that MAP changes nearly always were accompanied by flushing and histamine release (70,73,78).…”

Section: Allergic-type Event Frequency and Mast Cell Dependencementioning

confidence: 99%

See 1 more Smart Citation

MRGPRX2 and Adverse Drug Reactions

McNeil

2021

Front. Immunol.

View full text Add to dashboard Cite

Many adverse reactions to therapeutic drugs appear to be allergic in nature, and are thought to be triggered by patient-specific Immunoglobulin E (IgE) antibodies that recognize the drug molecules and form complexes with them that activate mast cells. However, in recent years another mechanism has been proposed, in which some drugs closely associated with allergic-type events can bypass the antibody-mediated pathway and trigger mast cell degranulation directly by activating a mast cell-specific receptor called Mas-related G protein-coupled receptor X2 (MRGPRX2). This would result in symptoms similar to IgE-mediated events, but would not require immune priming. This review will cover the frequency, severity, and dose-responsiveness of allergic-type events for several drugs shown to have MRGPRX2 agonist activity. Surprisingly, the analysis shows that mild-to-moderate events are far more common than currently appreciated. A comparison with plasma drug levels suggests that MRGPRX2 mediates many of these mild-to-moderate events. For some of these drugs, then, MRGPRX2 activation may be considered a regular and predictable feature after administration of high doses.

show abstract